Skip to content
Screener

PP&E (Net) at other companies

Rogers Corporation logo
Rogers CorporationROG
$358.2M-6.4%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$73.22M+23.6%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$235M-8.1%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$5.54M-21.2%
Opko Health logo
Opko HealthOPK
$71.45M-4.6%
LQD
Liquidia CorporationLQDA
$20.84M+146%

Segments

By geography

See full
Switzerland$91.29M
U.S.$6.37M
France$782K
Canada$433K

Other financials

Income statement

See full
Revenue$83.2M+18.9%
Gross profit$76.7M+21.9%
Operating income$46.3M+131%
Net income$37.4M+73.9%
EPS (diluted)$0.28+75.0%

Balance sheet

See full
Cash & equivalents$179.8M+239%
Total debt$80.6M-17.7%
Total equity$614.9M+83.4%
Total assets$792.3M+57.6%

Cash flow

See full
Operating cash flow$52.6M+18.8%

Valuation

See full
Market cap$2.07B+40.2%
Enterprise value$1.98B+29.7%
P/E6.6×-17.8×
P/S6.7×+1.0×

Profitability

See full
Gross margin90.4%+0.8pp
Operating margin48.4%+28.4pp
Net margin100.8%+77.5pp

Returns & leverage

See full
Return on equity66.1%+48.8pp
Debt / equity0.1×-0.2×
Current ratio5.4×+0.2×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:16 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001600620-26-000062
Line itemJune 30,2026December 31,2025
Finance right-of-use lease assets65,15273,865
Intangible assets, net3,3783,761
Operating right-of-use lease assets1,5183,596
Property and equipment, net1,8622,111
Other noncurrent assets9393
Total assets$792,262$751,587
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:

Item 1. Financial Statements.

FAQ

What is Aurinia Pharmaceuticals's PP&E (net)?
Aurinia Pharmaceuticals (AUPH) reported PP&E (net) of $1.86M in Q2 2026.
How has Aurinia Pharmaceuticals's PP&E (net) changed year-over-year?
Aurinia Pharmaceuticals's PP&E (net) decreased by 23.1% year-over-year, from $2.42M to $1.86M.
What is the long-term trend for Aurinia Pharmaceuticals's PP&E (net)?
Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's PP&E (net) has grown at a -15.1% compound annual growth rate (CAGR), from $4.79M to $2.11M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Ask your AI about Aurinia Pharmaceuticals's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude